News >

CHOP-RIT Superior for PFS Versus R-CHOP in High-Risk Follicular Lymphoma

Jason Harris
Published: Tuesday, Jan 23, 2018

Mazyar Shadman, MD

Mazyar Shadman, MD
The CHOP-RIT regimen improved progression-free survival (PFS) compared with R-CHOP alone in previously untreated patients with follicular lymphoma (FL), according to findings from the phase III SWOG-S0016 trial published in the Journal of Clinical Oncology.

= .08) for patients with bulky stage II disease versus patients with stage III to IV disease.
Shadman M, Li H, Rimsza L, et al. Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus rituximab or CHOP plus 131I-tositumomab: long-term follow-up of phase III randomized study SWOG-S0016 [published online January 22, 2018]. J Clin Oncol. doi: 10.1200/jco.2017.74.5083.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 3rd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesNov 29, 20192.0
Advances in™ ALL: The Role of T-Cell Engaging Immunotherapy in Treating Relapsed DiseaseNov 30, 20191.0
Publication Bottom Border
Border Publication